NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep/LinkedIn
Dec 3, 2025, 07:54

Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT

Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:

”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.

This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.

Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.

Patients living with HHT can’t wait for effective therapies to improve their lives.”

Quoting Vaderis Therapeutics AG‘s post:

”Moving Forward Together for the HHT Community

We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).

This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.

While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.

As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.

Read the full press release.”

Stay updated with Hemostasis Today.

bleeding disorders Darryl Sleep engasertib Health Hematology Hemostasis Hemostasis Today Hereditary Hemorrhagic Telangiectasia HEROIC HHT Medicine NEJM The New England Journal of Medicine VAD044 Vaderis
NewsFeed